A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy

Drug Safety

Volumn 27, Issue 7, 2004, Pages 421-426

  Chan, Vivian S W ^a  

^a HEALTH SCIENCES AUTHORITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; STEROID HORMONE; VALDECOXIB;

CHRONIC KIDNEY FAILURE; CONGENITAL MALFORMATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG LABELING; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DYSMENORRHEA; ENZYME ACTIVITY; ENZYME INHIBITION; GENITAL SYSTEM; GESTATION PERIOD; GOUT; HORMONE ACTION; HUMAN; INFERTILITY; KIDNEY DYSFUNCTION; LOW BIRTH WEIGHT; NEWBORN DISEASE; NONHUMAN; OLIGOHYDRAMNIOS; OSTEOARTHRITIS; PAIN; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPRODUCTION; REPRODUCTIVE TOXICITY; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; VASCULAR DISEASE;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; ISOXAZOLES; LACTONES; MEMBRANE PROTEINS; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; PYRIDINES; SULFONAMIDES; SULFONES;

EID: 2942547744     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427070-00001     Document Type: Review

References (38)

1. Fang YJ, Fok BSP, Tomlinson B. Etoricoxib: a new highly selective COX-2 inhibitor. Medical Prog 2003 Nov, 33-9
2. Tacca MD, Colucci R, Fornai M, et al. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Invest 2002; 22: 799-818
3. FitzGerald GA, Patrono C. The coxibs: selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42
4. MassHealth. Table 11: Nonsteroidal anti-inflammatory drugs [online]. Available from URL: http://www.state.ma.us/dma/ providers/pharmacy/theraputic/ MH_table-11.htm [Accessed 2004 Apr 26]
5. Celebrex no better than diclofenac. SCRIPT 2003; 28 (11/12): 23
6. Linder JD, Monkemuller KE, Davis JV, et al. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000; 93: 930-2
7. Schnitzer TJ. Cyclooxygenase-2-specific inhibitors: are they safe? Am J Med 2001; 110: 465-95
8. Graves JW, Hunder IA. Worsening of hypertension by drugs cyclo-oxygenase-2 inhibitors. J Clin Hypertens 2000; 2: 396-8
9. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9
10. Cardiovascular effect of COX inhibitors needs investigating. SCRIPT 2002; 2713: 24
11. H. Perazella MA. Hospital practice: COX-2 inhibitors and the kidney drugs [online]. Available from URL: http://www.hosppract.com/issues/2001/03/ceper.htm [Accessed 2004 Apr 26]
12. Sulverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the celecoxib long-term arthritis safety study (CLASS): a randomized controlled trial. JAMA 2000; 284: 1247-55
13. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclogenase-2 inhibitors. Cleve Clin J Med 2002; 29 Suppl. 1: S140-6
14. Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility. Drug Saf 2002; 25: 545-51
15. Schnitzer TJ. Cyclooxygenas-2-specific inhibitors: are they safe? Am J Med 2001; 110 (1A): 46S-9
16. Onn A, Tseng JE, Herbst RS. Thalidomide, cyclooxygnase-2, and angiogenesis. Clin Cancer Res 2001; 7: 3311-3
17. Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91: 197-208
18. Loftin CD, Trivedi DB, Tiano HF, et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci U S A. 2001; 98: 1059-64
19. Loftin CD, Trivedi DB, Langenbach R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest 2002; 110: 549-57
20. Reese J, Paria BC, Brown N, et al. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci U S A. 2000 Aug 15; 97: 9759-64
21. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthesis 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92
22. Dong YL, Gangula PR, Fang L, et al. Differential expression of cyclooxygenase-1 and -2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells. Prostaglandins 1996; 51: 13-34
23. Fang L, Chatterjee S, Dong YL, et al. Immunohistochemical localisation of constitutive and inducible cyclooxygenases in rat uterus during the oestrous cycle and pregnancy. Histochem J 1998; 30: 383-91
24. Fuchs A-R, Rust W, Fields MJ. Accumulation cyclooxygenase-2 gene transcripts in uterine tissues of pregnant and parturient cows: stimulated by oxytocin. Biol Reprod 1999; 60: 341-8
25. Slater D, Denned W, Sawdy R, et al. Expression of cyclooxygenase types-1 and -2 in human fetal membranes throughout pregnancy. J Mol Endocrinol 1999; 22: 125-30
26. Slater DM, Dennes WJ, Campa JS, et al. Expression of cyclooxygenase type-1 and -2 in human myometrium throughout pregnancy. Mol Hum Reprod 1999; 5: 880-4
27. Ishihara O, Matsuoka K, Kinoshita K, et al. Interleukin-l beta-stimulated PGE2 production from early first trimester inhibited by dexamethasone and progesterone. Prostaglandins 1995; 49: 15-26
28. Chakraborty I, Das SK, Wang J, et al. Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996; 16: 107-22
29. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-66
30. Summary of product characteristics of Bextra (valdecoxib) in UK [online]. Available from CTRL: http:// emc.medicines.org.uk [Accessed 2004 Apr 19]
31. Summary of product characteristics of Vioxx (rofecoxib) in UK [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Apr 19]
32. Summary of product characteristics of Arcoxia (etoricoxib) in UK [online]. Available from URL: http://emc. medicines.org.uk [Accessed 2004 Apr 19]
33. Summary of product characteristics of Celebrex (celecoxib) in UK [online]. Available from URL: http://emc. medicines.org.uk [Accessed 2004 Apr 19]
34. Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001; 358: 1287-8
35. Nielsen GL, Sorensen HT, Larsen H, et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322: 266-70
36. Loudon JA, Groom KM, Bennett PR. Prostaglandin inhibitors in preterm labour. Best Pract Res Clin Obstet Gynaecol 2003; 17: 731-44
37. Peruzzi L, Gianoglio B, Porcellini G, et al. Neonatal chronic kidney failure associated with cyclo-oxygenase-2 inhibitors administered during pregnancy. Minerva Urol Nefrol 2001; 53: 113-6
38. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2001; 327: 368-71